Antimicrobial use, drug-resistant infections and COVID-19

Coronavirus disease 2019 may have a complex long-term impact on antimicrobial resistance (AMR). Coordinated strategies at the individual, health-care and policy levels are urgently required to inform necessary actions to reduce the potential longer-term impact on AMR and on access to effective antim...

Descripción completa

Detalles Bibliográficos
Autores principales: Rawson, Timothy M., Ming, Damien, Ahmad, Raheelah, Moore, Luke S. P., Holmes, Alison H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264971/
https://www.ncbi.nlm.nih.gov/pubmed/32488173
http://dx.doi.org/10.1038/s41579-020-0395-y
_version_ 1783541041872240640
author Rawson, Timothy M.
Ming, Damien
Ahmad, Raheelah
Moore, Luke S. P.
Holmes, Alison H.
author_facet Rawson, Timothy M.
Ming, Damien
Ahmad, Raheelah
Moore, Luke S. P.
Holmes, Alison H.
author_sort Rawson, Timothy M.
collection PubMed
description Coronavirus disease 2019 may have a complex long-term impact on antimicrobial resistance (AMR). Coordinated strategies at the individual, health-care and policy levels are urgently required to inform necessary actions to reduce the potential longer-term impact on AMR and on access to effective antimicrobials.
format Online
Article
Text
id pubmed-7264971
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72649712020-06-02 Antimicrobial use, drug-resistant infections and COVID-19 Rawson, Timothy M. Ming, Damien Ahmad, Raheelah Moore, Luke S. P. Holmes, Alison H. Nat Rev Microbiol Comment Coronavirus disease 2019 may have a complex long-term impact on antimicrobial resistance (AMR). Coordinated strategies at the individual, health-care and policy levels are urgently required to inform necessary actions to reduce the potential longer-term impact on AMR and on access to effective antimicrobials. Nature Publishing Group UK 2020-06-02 2020 /pmc/articles/PMC7264971/ /pubmed/32488173 http://dx.doi.org/10.1038/s41579-020-0395-y Text en © Springer Nature Limited 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
Rawson, Timothy M.
Ming, Damien
Ahmad, Raheelah
Moore, Luke S. P.
Holmes, Alison H.
Antimicrobial use, drug-resistant infections and COVID-19
title Antimicrobial use, drug-resistant infections and COVID-19
title_full Antimicrobial use, drug-resistant infections and COVID-19
title_fullStr Antimicrobial use, drug-resistant infections and COVID-19
title_full_unstemmed Antimicrobial use, drug-resistant infections and COVID-19
title_short Antimicrobial use, drug-resistant infections and COVID-19
title_sort antimicrobial use, drug-resistant infections and covid-19
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264971/
https://www.ncbi.nlm.nih.gov/pubmed/32488173
http://dx.doi.org/10.1038/s41579-020-0395-y
work_keys_str_mv AT rawsontimothym antimicrobialusedrugresistantinfectionsandcovid19
AT mingdamien antimicrobialusedrugresistantinfectionsandcovid19
AT ahmadraheelah antimicrobialusedrugresistantinfectionsandcovid19
AT moorelukesp antimicrobialusedrugresistantinfectionsandcovid19
AT holmesalisonh antimicrobialusedrugresistantinfectionsandcovid19

Ejemplares similares